MDM-2 oncoprotein overexpression, p53 gene mutation, and VEGF up- regulation in angiosarcomas

American Journal of Pathology

Volumn 153, Issue 5, 1998, Pages 1425-1433

  Zietz, Christian ^a   Rössle, Matthias ^a   Haas, Christian ^a   Sendelhofert, Andrea ^a   Hirschmann, Astrid ^a   Stürzl, Michael ^b   Löhrs, Udo ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOPROTEIN; PROTEIN P53; VASCULOTROPIN;

ADULT; AGED; ANGIOSARCOMA; ARTICLE; CLINICAL ARTICLE; DNA BINDING; FEMALE; GENE MUTATION; GENE OVEREXPRESSION; GENE SEQUENCE; HEMANGIOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTO ONCOGENE; SEQUENCE ANALYSIS;

EID: 0031737424     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)65729-X     Document Type: Article

References (46)

1. Jaffe EA: Cell biology of endothelial cells. Hum Pathol 1987, 18:234-239
2. Denekamp J: Review article: angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br J Radiol 1993, 66:181-196
3. Folkman J: Seminars in medicine of the Beth Israel Hospital, Boston: clinical applications of research on angiogenesis. N Engl J Med 1995, 333:1757-1763
4. Malignant vascular tumors. In Soft Tissue Tumors. Edited by FM Enzinger and SW Weiss. Mosby, St. Louis. 1996, 641-677
5. Levine AJ: p53, the cellular gatekeeper for growth and division. Cell 1997, 88:323-331
6. Bosari S, Viale G: The clinical significance of p53 aberrations in human tumours. Virchows Arch 1995, 427:229-241
7. Greenblatt MS, Bennett WP, Hollstein M, Harris CC: Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994, 54:4855-4878
8. Beroud C, Verdier F, Soussi T: p53 gene mutation: software and database. Nucleic Acids Res 1996, 24:147-150
9. Hollstein M, Shomer B, Greenblatt M, Soussi T, Hovig E, Montesano R, Harris CC: Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation. Nucleic Acids Res 1996, 24:141-146
10. Momand J, Zambetti GP, Olson DC, George D, Levine AJ: The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992, 69:1237-1245
11. Momand J, Zambetti GP: Mdm-2: "big brother" of p53. J Cell Biochem 1997, 64:343-352
12. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B: Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992, 358:80-83
13. Leach FS, Tokino T, Meltzer P, Burrell M, Oliner JD, Smith S, Hill DE, Sidransky D, Kinzler KW, Vogelstein B: p53 Mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res 1993, 53: 2231-2234
14. Ladanyi M, Cha C, Lewis R, Jhanwar SC, Huvos AG, Healey JH: MDM2 gene amplification in metastatic osteosarcoma: Cancer Res 1993, 53:16-18
15. Keleti J, Quezado MM, Abaza MM, Raffeld M, Tsokos M: The MDM2 oncoprotein is overexpressed in rhabdomyosarcoma cell lines, and stabilizes wild-type p53 protein. Am J Pathol 1996, 149:143-151
16. Cordon Cardo C, Latres E, Drobnjak M, Oliva MR, Pollack D, Woodruff JM, Marechal V, Chen J, Brennan MF, Levine AJ: Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res 1994, 54:794-799
17. Muknopadhyay D, Tsiokas L, Sukhatme VP: Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression. Cancer Res 1995, 55:6161-6165
18. Kieser A, Weich HA, Brandner G, Marme D, Kolch W: Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene 1994, 9:963-969
19. Rosai J, Carcangiu ML, DeLellis RA: Sarcomas. In: Tumors of the Thyroid Gland. Edited by J Rosai and LH Sobin. Washington, DC, Armed Forces Institute of Pathology, 1992, 259-265
20. Hollstein M, Marion MJ, Lehman T, Welsh J, Harris CC, Martel Planche G, Kusters I, Montesano R: p53 mutations at A:T base pairs in angiosarcomas of vinyl chloride-exposed factory workers. Carcinogenesis 1994, 15:1-3
21. Trivers GE, Cawley HL, DeBenedetti VM, Hollstein M, Marion MJ, Bennett WP, Hoover ML, Prives CC, Tamburro CC, Harris CC. Anti-p53 antibodies in sera of workers occupationally exposed to vinyl chloride. J Natl Cancer Inst 1995, 87:1400-1407
22. Soini Y, Welsh JA, Ishak KG, Bennett WP: p53 mutations in primary hepatic angiosarcomas not associated with vinyl chloride exposure. Carcinogenesis 1995, 16:2879-2881
23. Rosen PR, Oberman HA: Angiosarcoma. In: Tumors of Mammary Gland. Edited by J Rosai and LH Sobin. Washington, DC, Armed Forces Institute of Pathology, 1993, 320-328
24. Rosen PR, Oberman HA: Postmastectomy angiosarcoma. In: Tumors of Mammary Gland. Edited by J Rosai and LH Sobin. Washington, DC, Armed Forces Institute of Pathology, 1993, 328-334
25. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hosteller R, Cleary K, Bigner SH, Davidson N, Baylin S, Devilee P, Glover T, Collins FS, Weston A, Modali R, Harris CC, Vogelstein B: Mutations in the p53 gene occur in diverse human tumour types. Nature 1989, 342:705-708
26. McAllister HA, Fenoglio JJ: Angiosarcoma. In: Tumors of the Thyroid Gland. Edited by J Rosai and LH Sobin. Washington, DC, Armed Forces Institute of Pathology, 1978, 81-88
27. Burke A, Virmandi R: Angiosarcoma. In: Tumors of the Heart and Great Vessels. Edited by J Rosai and LH Sobin. Washington, DC, Armed Forces Institute of Pathology, 1996, 136-140
28. Fechner RE, Mills SE: Angiosarcoma. In: Tumors of the Bones and Joints. Edited by J Rosai and LH Sobin. Washington, DC, Armed Forces Institute of Pathology, 1993, 138-140
29. DeYong BR, Wick MR, Fitzgibbon JF: CD31: an immunospecific marker for endothelial differentiation in human neoplasms. Appl Immunohistochem 1993, 1:97-100
30. Coindre JM, Trojani M, Contesso G, David M, Rouesse J, Bui NB, Bodaert A, DeMoscarel I, DeMoscarel A, Goussot JF: Reproducibility of a histopathologic grading system for adult soft tissue sarcoma. Cancer 1986, 58:306-309
31. Hsu SM, Raine L, Fanger H: The use of antiavidin antibody and avidin-biotin-peroxidase complex in immunoperoxidase technics. Am J Clin Pathol. 1981, 75:816-821
32. Hsu SM, Raine L, Fanger H: Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques, a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981, 29:577-580
33. Remmele W, Hildebrand U, Hienz HA, Klein PJ, Vierbuchen M, Behnken LJ, Heicke B, Scheidt E: Comparative histological, histochemical, immunohistochemical and biochemical studies on oestrogen receptors, lectin receptors, and Barr bodies in human breast cancer. Virchows Arch A Pathol Anat Histopathol 1986, 409:127-147
34. Fischer SG, Lerman LS: Separation of random fragments of DNA according to properties of their sequences. Proc Natl Acad Sci USA 1980, 77:4420-4424
35. Sheffield VC, Cox DR, Lerman LS, Myers RM: Attachment of a 40-base-pair G + C-rich sequence (GC-clamp) to genomic DNA fragments by the polymerase chain reaction results in improved detection of single-base changes. Proc Natl Acad Sci USA 1989, 86:232-236
36. Beck JS, Kwitek AE, Cogen PH, Metzger AK, Duyk GM, Sheffield VC: A denaturing gradient gel electrophoresis assay for sensitive detection of p53 mutations. Hum Genet 1993, 91:25-30
37. Borresen AL, Hovig E, Smith Sorensen B, Malkin D, Lystad S, Andersen TI, Nesland JM, Isselbacher KJ, Friend SH: Constant denaturant gel electrophoresis as a rapid screening technique for p53 mutations. Proc Natl Acad Sci USA 1991, 88:8405-8409
38. Naka N, Tomita Y, Nakanishi H, Araki N, Hongyo T, Ochi T, Aozasa K: Mutations of p53 tumor-suppressor gene in angiosarcoma. Int J Cancer 1997, 71:952-955
39. Dameron KM, Volpert OV, Tainsky MA, Bouck N: Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994, 265:1582-1584
40. Dameron KM, Volpert OV, Tainsky MA, Bouck N: The p53 tumor suppressor gene inhibits angiogenesis by stimulating the production of thrombospondin. Cold Spring Harb Symp Quant Biol 1994, 59: 483-489
41. Reed MJ, Iruela Arispe L, O'Brien ER, Truong T, LaBell T, Bornstein P, Sage EH: Expression of thrombospondins by endothelial cells. Injury is correlated with TSP-1. Am J Pathol 1995, 147:1068-1080
42. Bornstein P, Sage EH: Thrombospondins: Methods Enzymol 1994, 245:62-85
43. Sheibani N, Frazier WA: Thrombospondin 1 expression in transformed endothelial cells restores a normal phenotype, and sup-presses their tumorigenesis. Proc Natl Acad Sci USA 1995, 92:6788-6792
44. Good DJ, Polverini PJ, Rastinejad F, Le Beau MM, Lemons RS, Frazier WA, Bouck NP: A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci USA 1990, 87:6624-6628
45. Lawler J: The structural and functional properties of thrombospondin. Blood 1986, 67:1197-1209
46. Takahashi K, Mulliken JB, Kozakewich HP, Rogers RA, Folkman J, Ezekowitz RA: Cellular markers that distinguish the phases of hemangioma during infancy and childhood J Clin Invest 1994, 93:2357-2364